You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK)曾漲逾一成 子公司復邁寧獲藥品註冊批准
阿思達克 05-30 14:44
復星醫藥(02196.HK)今日(30日)高開2.27%,曾漲10.3%高見16.5元。現報16.38元,升9.49%,成交3,040.45萬股,涉資4.88億元。 復星醫藥控股子公司上海復星醫藥產業就蘆沃美替尼片(商品名:復邁寧)的上市註冊申請獲國家藥品監督管理局批准。復邁寧本次獲批的兩項適應症分別用於治療朗格漢斯細胞組織細胞增生症(LCH)和組織細胞腫瘤成人患者,以及2歲及2歲以上伴有症狀、無法手術的叢狀神經纖維瘤(PN)的I型神經纖維瘤病(NF1)兒童及青少年患者。 據悉,這是上海今年第6款獲批上市的國產1類創新藥,也是近期又一款獲批上市的罕見病用藥。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account